Jul 30, 2019
Overview Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including, but not limited to, advancement of the asset(s) in...
May 20, 2019
Brian Coleman, Locust Walk’s Managing Director, Global Head of Financing and Sales will be moderating the panel, Drawing Your Financing Roadmap, at BioEquity Europe: Faced with an expanding range of financing options, early stage biotech executives must figure...
Nov 2, 2017
Besides calling the Ghostbusters, how does one catch a ghost? That is the question asked by most life science companies trying to raise capital from family offices, which we define as a non-institutional investor capable of investing $1M or more into an individual...
Oct 25, 2017
For many years, the fundraising environment for MedTech companies has been exceedingly difficult. Venture firms that were historically active in MedTech shifted their investment allocations to other areas of life sciences and capital became constrained. New entrants...
Aug 8, 2017
As an early advocate for the importance of the family office in the biotech financing landscape, I have learned from recent experience what many entrepreneurs already know. Raising money from family offices is hard. While there are several challenges to attracting...
Aug 2, 2016
When the financial crisis of 2008 hit and many VCs went out of business, capital available for entrepreneurs with a molecule and a dream dwindled dramatically. The surviving VCs are now much stronger yet bifurcate between early-stage, in which they start the...
